- Raw materials
- Antibacterials
- Garenoxacin
Garenoxacin API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Garenoxacin | CAS No: 194804-75-6 | GMP-certified suppliers
A medication that targets bacterial infections by inhibiting DNA replication, under investigation for systemic use against gram-positive and gram-negative pathogens with antibacterial benefits.
Therapeutic categories
Primary indications
- Investigated for use/treatment in bacterial infection
Product Snapshot
- Garenoxacin is an oral small molecule antibiotic
- It is primarily investigated for the treatment of bacterial infections
- The compound is currently in the investigational stage without approved marketing authorization
Clinical Overview
The compound functions as an antibacterial agent targeting bacterial DNA replication processes. As a fluoroquinolone, Garenoxacin exerts its antimicrobial effects primarily through inhibition of bacterial topoisomerase II (DNA gyrase) and topoisomerase IV enzymes. These enzymes are critical for DNA supercoiling and segregation during bacterial cell division, and their inhibition results in impaired DNA replication and bacterial cell death.
Pharmacokinetic data for Garenoxacin indicate systemic availability suitable for treating systemic infections. Garenoxacin is recognized as a moderate risk agent for QTc prolongation, which necessitates careful consideration in patients with predisposing cardiac conditions or concomitant medications with similar effects. It is also a reported inhibitor of cytochrome P450 enzyme CYP1A2; however, the inhibitory strength and clinical significance require further characterization.
To date, Garenoxacin remains investigational and has not received regulatory approval for therapeutic use in major markets. It has been evaluated within clinical contexts targeting bacterial infections, with potential applications inclusive of respiratory and urinary tract infections.
Safety considerations include monitoring for adverse effects common to quinolones, such as potential tendon toxicity, central nervous system effects, and photosensitivity, alongside considerations for its impact on cardiac electrophysiology.
For API procurement, quality control should focus on confirming identity and purity consistent with quinolone carboxylic acid standards and ensuring absence of impurities that could affect safety or efficacy. Given its role as a cytochrome P450 inhibitor and QTc prolonging agent, detailed characterization of the API’s physicochemical properties and stability profile is advised to support formulation and regulatory submission processes.
Identification & chemistry
| Generic name | Garenoxacin |
|---|---|
| Molecule type | Small molecule |
| CAS | 194804-75-6 |
| UNII | V72H9867WB |
| DrugBank ID | DB06160 |
Formulation & handling
- Garenoxacin is a small molecule quinoline carboxylic acid typically formulated for oral administration.
- Its low water solubility suggests the need for formulation strategies to enhance bioavailability.
- Handle under standard conditions as a solid compound with no specific peptide or biological stability concerns reported.
Regulatory status
Garenoxacin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
